FDA removes epinephrine from COVID-19 temporary compounding list

Oct 16, 2020 - 03:13 PM
FDA-guidance

The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.

FDA said epinephrine’s removal is based on increased supplies of FDA-approved epinephrine products used to treat hospitalized COVID-19 patients.

Related News Articles

Headline
CDC adopts ACIP recommendations for COVID-19, chickenpox vaccines
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
FDA seeks feedback on measuring AI-enabled medical device performance
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
Olympus recalls endoscope needles
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
HHS announces efforts to improve long COVID care 
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
FDA issues serious recall for electric wheelchair joysticks
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…